Seer Posts $16.8M Loss Amid $2.7M Revenue

Forward-Looking Analysis

Based on the provided news content, there are no forward-looking financial estimates, analyst predictions, or earnings consensus data available for Seer (SEER) for the 2026Q2 period. The provided text contains irrelevant information regarding ITC Ltd, Nucor Corporation, Apple, and general astrological or weather forecasts, but explicitly lacks specific revenue, net profit, or EPS projections for Seer. Consequently, no analyst upgrades, downgrades, or price targets for Seer can be extracted from the source material. The only forward-looking statement available is the confirmed announcement date for the financial results.

Historical Performance Review

Seer’s 2026Q1 performance reflected significant financial challenges, reporting a total revenue of $2.71 million. The company posted a substantial net income loss of $16.84 million, resulting in an earnings per share (EPS) of -$0.30. Gross profit was recorded at a modest $982.00 thousand, highlighting the disparity between top-line sales and operational costs during the quarter. These figures indicate a heavy burn rate relative to current revenue generation capabilities.

Additional News

Seer, Inc. (Nasdaq: SEER) officially announced on August 3, 2026, that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026. The company plans to host a conference call for management to discuss these results, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of this webcast will be accessible via the Investor section of Seer’s website at investor.seer.bio, with an archived replay available post-event. Seer continues to operate as a pioneer in deep, unbiased proteomics, utilizing its proprietary Proteograph Product Suite, which integrates engineered nanoparticles and advanced software for research use only. Current market data indicates the stock trades around $1.83, with a market cap of approximately $103.92 million.

Summary & Outlook

Seer’s financial health remains precarious, characterized by minimal revenue of $2.71 million against a massive net loss of $16.84 million in Q1 2026. The primary growth catalyst is its proprietary proteomic technology, yet the company faces significant risk due to its deep negative EPS of -$0.30 and low gross profit margins. With a negative P/E ratio and a market cap under $105 million, the stock exhibits high volatility. Given the substantial operational losses relative to sales, the outlook is bearish in the near term, as the company must demonstrate a clear path to profitability to sustain investor confidence amid broader market pressures.